全文获取类型
收费全文 | 1332951篇 |
免费 | 102055篇 |
国内免费 | 4243篇 |
专业分类
耳鼻咽喉 | 16802篇 |
儿科学 | 43573篇 |
妇产科学 | 36358篇 |
基础医学 | 197859篇 |
口腔科学 | 36008篇 |
临床医学 | 129471篇 |
内科学 | 257873篇 |
皮肤病学 | 26375篇 |
神经病学 | 111837篇 |
特种医学 | 48173篇 |
外国民族医学 | 366篇 |
外科学 | 184024篇 |
综合类 | 28768篇 |
现状与发展 | 1篇 |
一般理论 | 460篇 |
预防医学 | 114229篇 |
眼科学 | 28974篇 |
药学 | 98822篇 |
6篇 | |
中国医学 | 3170篇 |
肿瘤学 | 76100篇 |
出版年
2021年 | 10905篇 |
2019年 | 11645篇 |
2018年 | 16318篇 |
2017年 | 12304篇 |
2016年 | 13262篇 |
2015年 | 15205篇 |
2014年 | 20824篇 |
2013年 | 32077篇 |
2012年 | 44281篇 |
2011年 | 46933篇 |
2010年 | 27101篇 |
2009年 | 24943篇 |
2008年 | 42742篇 |
2007年 | 45090篇 |
2006年 | 45191篇 |
2005年 | 43610篇 |
2004年 | 41571篇 |
2003年 | 39503篇 |
2002年 | 38316篇 |
2001年 | 60846篇 |
2000年 | 62511篇 |
1999年 | 52283篇 |
1998年 | 14587篇 |
1997年 | 13275篇 |
1996年 | 13117篇 |
1995年 | 12458篇 |
1994年 | 11625篇 |
1993年 | 10922篇 |
1992年 | 41569篇 |
1991年 | 40761篇 |
1990年 | 39445篇 |
1989年 | 37340篇 |
1988年 | 34581篇 |
1987年 | 33695篇 |
1986年 | 32150篇 |
1985年 | 30638篇 |
1984年 | 23036篇 |
1983年 | 19592篇 |
1982年 | 11752篇 |
1979年 | 20806篇 |
1978年 | 14816篇 |
1977年 | 12066篇 |
1976年 | 11876篇 |
1975年 | 12110篇 |
1974年 | 14800篇 |
1973年 | 14472篇 |
1972年 | 13356篇 |
1971年 | 12418篇 |
1970年 | 11487篇 |
1969年 | 10411篇 |
排序方式: 共有10000条查询结果,搜索用时 218 毫秒
181.
182.
183.
184.
185.
186.
187.
L. Misery E. Weisshaar E. Brenaut A.W.M. Evers F. Huet S. Ständer A. Reich E. Berardesca E. Serra-Baldrich J. Wallengren D. Linder J.W. Fluhr J.C. Szepietowski H. Maibach for the Special Interest Group on sensitive skin of the International Forum for the Study of Itch 《Journal of the European Academy of Dermatology and Venereology》2020,34(2):222-229
The special interest group on sensitive skin of the International Forum for the Study of Itch previously defined sensitive skin as a syndrome defined by the occurrence of unpleasant sensations (stinging, burning, pain, pruritus and tingling sensations) in response to stimuli that normally should not provoke such sensations. This additional paper focuses on the pathophysiology and the management of sensitive skin. Sensitive skin is not an immunological disorder but is related to alterations of the skin nervous system. Skin barrier abnormalities are frequently associated, but there is no cause and direct relationship. Further studies are needed to better understand the pathophysiology of sensitive skin – as well as the inducing factors. Avoidance of possible triggering factors and the use of well-tolerated cosmetics, especially those containing inhibitors of unpleasant sensations, might be suggested for patients with sensitive skin. The role of psychosocial factors, such as stress or negative expectations, might be relevant for subgroups of patients. To date, there is no clinical trial supporting the use of topical or systemic drugs in sensitive skin. The published data are not sufficient to reach a consensus on sensitive skin management. In general, patients with sensitive skin require a personalized approach, taking into account various biomedical, neural and psychosocial factors affecting sensitive skin. 相似文献
188.
189.
Catherine L. Omosule Dominique Joseph Brooke Weiler Victoria L. Gremminger Spencer Silvey Youngjae Jeong Ashique Rafique Pamela Krueger Sandra Kleiner Charlotte L. Phillips 《Journal of bone and mineral research》2022,37(5):938-953
Osteogenesis imperfecta (OI) is a collagen-related bone disorder characterized by fragile osteopenic bone and muscle weakness. We have previously shown that the soluble activin receptor type IIB decoy (sActRIIB) molecule increases muscle mass and improves bone strength in the mild to moderate G610C mouse model of OI. The sActRIIB molecule binds multiple transforming growth factor-β (TGF-β) ligands, including myostatin and activin A. Here, we investigate the musculoskeletal effects of inhibiting activin A alone, myostatin alone, or both myostatin and activin A in wild-type (Wt) and heterozygous G610C (+/G610C) mice using specific monoclonal antibodies. Male and female Wt and +/G610C mice were treated twice weekly with intraperitoneal injections of monoclonal control antibody (Ctrl-Ab, Regn1945), anti-activin A antibody (ActA-Ab, Regn2476), anti-myostatin antibody (Mstn-Ab, Regn647), or both ActA-Ab and Mstn-Ab (Combo, Regn2476, and Regn647) from 5 to 16 weeks of age. Prior to euthanasia, whole body composition, metabolism and muscle force generation assessments were performed. Post euthanasia, hindlimb muscles were evaluated for mass, and femurs were evaluated for changes in microarchitecture and biomechanical strength using micro–computed tomography (μCT) and three-point bend analyses. ActA-Ab treatment minimally impacted the +/G610C musculoskeleton, and was detrimental to bone strength in male +/G610C mice. Mstn-Ab treatment, as previously reported, resulted in substantial increases in hindlimb muscle weights and overall body weights in Wt and male +/G610C mice, but had minimal skeletal impact in +/G610C mice. Conversely, the Combo treatment outperformed ActA-Ab alone or Mstn-Ab alone, consistently increasing hindlimb muscle and body weights regardless of sex or genotype and improving bone microarchitecture and strength in both male and female +/G610C and Wt mice. Combinatorial inhibition of activin A and myostatin more potently increased muscle mass and bone microarchitecture and strength than either antibody alone, recapturing most of the observed benefits of sActRIIB treatment in +/G610C mice. © 2022 American Society for Bone and Mineral Research (ASBMR). 相似文献
190.
Archie L. Overmann DesRaj M. Clark Panagiotis Tsagkozis Rikard Wedin Jonathan A. Forsberg 《Journal of orthopaedic research》2020,38(10):2149-2156
Treatment decisions in patients with metastatic bone disease rely on accurate survival estimation. We developed the original PATHFx models using expensive, proprietary software and now seek to provide a more cost-effective solution. Using open-source machine learning software to create PATHFx version 2.0, we asked whether PATHFx 2.0 could be created using open-source methods and externally validated in two unique patient populations. The training set of a well-characterized, database records of 189 patients and the bnlearn package within R Version 3.5.1 (R Foundation for Statistical Computing), was used to establish a series of Bayesian belief network models designed to predict survival at 1, 3, 6, 12, 18, and 24 months. Each was externally validated in both a Scandinavian (n = 815 patients) and a Japanese (n = 261 patients) data set. Brier scores and receiver operating characteristic curves to assessed discriminatory ability. Decision curve analysis (DCA) evaluated whether models should be used clinically. DCA showed that the model should be used clinically at all time points in the Scandinavian data set. For the 1-month time point, DCA of the Japanese data set suggested to expect better outcomes assuming all patients will survive greater than 1 month. Brier scores for each curve demonstrate that the models are accurate at each time point. Statement of Clinical Significance: we successfully transitioned to PATHFx 2.0 using open-source software and externally validated it in two unique patient populations, which can be used as a cost-effective option to guide surgical decisions in patients with metastatic bone disease. 相似文献